Physician profile
Michael Allen Schaffer
NPI 1730280777
$1,852.62
in general payments reported to CMS, 2019-2025
26 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $259 · 2021: $171 · 2022: $348 · 2023: $174 · 2024: $263 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $407.06 | 2019-2023 | Tepezza |
| Abbvie INC. | $181.87 | 2023-2025 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $171.78 | 2019 | |
| Dompe US, INC. | $156.06 | 2020-2025 | Oxervate |
| Amgen INC. | $108.51 | 2024-2025 | Tepezza |
| Tearlab Corp | $104.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $96.82 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $93.35 | 2022-2025 | Miebo, Xipere, Xiidra |
| Harrow Eye, LLC | $68.70 | 2025 | Vevye |
| Astellas Pharma US INC | $54.49 | 2023-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $51.11 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $48.53 | 2020-2025 | Eylea, Eylea Hd |
| Tarsus Pharmaceuticals, INC. | $44.38 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $33.64 | 2024 | Syfovre |
| Glaukos Corporation | $28.02 | 2025 | Idosetr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $23.71 | 2023 | |
| Alimera Sciences, INC. | $21.97 | 2020 | |
| Kala Pharmaceuticals, INC. | $20.32 | 2020 | |
| Oyster Point Pharma, INC. | $19.64 | 2024 | Ryzumvi, Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $19.03 | 2022 | |
| Avita Medical Americas, LLC | $17.66 | 2023 | Recell |
| Mallinckrodt Hospital Products INC. | $17.03 | 2020 | |
| Eyevance Pharmaceuticals LLC | $16.85 | 2019 | |
| Allergan, INC. | $15.64 | 2021 | |
| Aerie Pharmaceuticals, INC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.